Latest University of Maryland School of Medicine Stories
Study provides first direct evidence of cigarette smoke's role in the death of transplanted hearts.
Researchers at the University of Maryland School of Medicine have made an important discovery about why potassium builds up to dangerous levels in the bloodstream, a relatively common medical problem that affects about eight percent of hospitalized patients.
Surgical treatment for mitral valve disease includes either repairing the patient's diseased valve or replacing it with a metal, mechanical valve or an animal tissue valve.
Findings reveal further detail about protein linked to inflammatory disorders.
Researchers at the University of Maryland Marlene and Stewart Greenebaum Cancer have found that head and neck cancer patients who test positive for the human papillomavirus (HPV) have much better survival rates than patients who don't have the virus, according to a new study in the journal Cancer Prevention Research.
Project SHALEM: Partnering with the Faith-Based Community to Test in a 'Safe Place'BALTIMORE, July 21 /PRNewswire-USNewswire/ -- Today, the JACQUES Initiative, a program of the Institute of Human Virology (IHV) at the University of Maryland School of Medicine, in partnership with the Maryland AIDS Administration, several local faith-based and community organizations kicked-off Project SHALEM during City Uprising Baltimore, a four day event sponsored by the Gallery Church Baltimore.
22nd Congress of the European College of Neuropsychopharmacology (ECNP), 12 - 16 September 2009, Istanbul, Turkey
University of Maryland researchers see potential new treatment approach in targeting immune response to virus.
"HIV/AIDS Remains the Number One Global Health Threat" WASHINGTON, May 8 /PRNewswire-USNewswire/ -- Today, HIV co-discoverers Drs. Robert C. Gallo, director of the Institute of Human Virology at the University of Maryland School of Medicine, and Luc A.
FDA approval for testing in humans watershed moment for unique malaria vaccine approach ROCKVILLE, Md., April 23 /PRNewswire/ -- In a move that highlights the strength of public-private collaboration in tackling international health challenges, the Maryland-based company Sanaria Inc., with support from the PATH Malaria Vaccine Initiative (MVI), has initiated a Phase 1 clinical trial -- the first tests in adult volunteers -- of its unique malaria vaccine candidate.
- totally perplexed and mixed up.